AC
NKTR icon

Alexandria Capital’s Nektar Therapeutics NKTR Stock Holding History

Alexandria Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,671
Closed -$430K – 263
2021
Q2 		$430K Sell
1,671
-3,810
-70% -$1.05M 0.04% 196
2021
Q1 		$1.64M Sell
5,481
-123
-2% -$38.3K 0.17% 129
2020
Q4 		$1.43M Sell
5,604
-982
-15% -$254K 0.15% 128
2020
Q3 		$1.64M Sell
6,586
-17
-0.3% -$5.35K 0.2% 123
2020
Q2 		$2.29M Buy
6,603
+28
+0.4% +$8.74K 0.3% 99
2020
Q1 		$1.76M Sell
6,575
-9
-0.1% -$2.78K 0.29% 95
2019
Q4 		$2.13M Sell
6,584
-89
-1% -$25.8K 0.29% 98
2019
Q3 		$1.82M Sell
6,673
-33
-0.5% -$12.1K 0.27% 101
2019
Q2 		$3.58M Buy
6,706
+4
+0.1% +$2.01K 0.51% 64
2019
Q1 		$3.38M Buy
6,702
+7
+0.1% +$4.15K 0.49% 68
2018
Q4 		$3.3M Sell
6,695
-18
-0.3% -$10.9K 0.54% 57
2018
Q3 		$6.14M Buy
6,713
+49
+0.7% +$41.8K 0.9% 31
2018
Q2 		$4.88M Buy
6,664
+8
+0.1% +$9.22K 0.73% 37
2018
Q1 		$10.6M Buy
6,656
+23
+0.3% +$29.6K 1.57% 12
2017
Q4 		$5.94M Buy
+6,633
New +$3.92M 0.87% 31

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Alexandria Capital's NKTR Position: Q3 2021 in Review

Alexandria Capital sold out of Nektar Therapeutics (NKTR) in Q3 2021, closing a stake of 1,671 shares — an estimated $430K sold.

Alexandria Capital first reported a position in NKTR in Q4 2017 and held it in 15 quarters. The position peaked at $10.6M in Q1 2018. 241 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.

  • Alexandria Capital reported no remaining Nektar Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Alexandria Capital sold 1,671 Nektar Therapeutics shares in Q3 2021, an estimated $430K.
  • Alexandria Capital first reported a position in Nektar Therapeutics in Q4 2017 and held it in 15 quarters.
  • Alexandria Capital's Nektar Therapeutics position peaked at $10.6M in Q1 2018.
  • 241 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.

Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.